Deciphera Pharmaceuticals, Inc. said it appointed Agios Pharmaceuticals Inc.'s chief commercial officer to its board.

The addition of Steven Hoerter to the Waltham, Mass.-based biopharmaceutical company's board increases its size to nine members from eight.

Deciphera expects Hoerter to assist the company as it advances its treatment, DCC-2618, for patients with gastrointestinal stromal tumors.

At Agios, Hoerter is responsible for the commercialization of the company's portfolio of medicines for oncology and rare genetic diseases.